23 May 2013
Keywords: cv, thera, initiates, cvt-3619, trial, usa-based, therapeutics
Article | 08 September 2008
USA-based CV Therapeutics has enrolled the first patient in a Phase I trial of CVT-3619, a partial A1 adenosine receptor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 September 2008
15 September 2008
1 September 2008
© 2013 thepharmaletter.com